Protagonist Therapeutics, Inc Proceeds from Sale and Maturity of Marketable Securities
Protagonist Therapeutics, Inc (PTGX) reported Proceeds from Sale and Maturity of Marketable Securities of $3.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-05
- Protagonist Therapeutics, Inc proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $0.00.
- Protagonist Therapeutics, Inc proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $3.38M, a 51.68% decline year-over-year.
- Protagonist Therapeutics, Inc proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $0.00.
- Protagonist Therapeutics, Inc proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $0.00.
- Protagonist Therapeutics, Inc proceeds from sale and maturity of marketable securities for fiscal 2025 was $7.00M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.38M 10-Q · filed 2026-08-05 | $3.38M derived: sum of 3 quarters · filed 2026-08-05 | $3.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.38M 10-Q · filed 2026-05-05 | $3.38M derived: sum of 2 quarters · filed 2026-05-05 | $3.38M derived: sum of 3 quarters · filed 2026-05-05 | $3.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $7.00M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $7.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.00M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $7.00M 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |